Horizon Discovery and Transgenomic have entered into a collaboration to develop genetic diagnostic tests. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls to Horizon’s quantitative molecular reference standards for all of its existing assays and for any new assays developed in the future.
As part of the agreement, Horizon will provide its renewable, genetically defined quantitative molecular reference standards in both genomic DNA and formalin fixed paraffin embedded format, through its Horizon Diagnostics division.
The quantitative molecular reference standards will be used for Transgenomic’s range of genetic diagnostic tests, and in the development of new tests and in vitro diagnostic testing kits. The reference standard products will be chosen from Horizon Diagnostics’ existing inventory of more than 300 products, and Horizon’s GENESIS™ gene editing platform will also be employed to engineer new lines as needed.
According to Horizon Diagnostics, its reference standard product portfolio comprises highly validated, engineered cell line derived material, including purified DNA with matched normal and renewable formalin fixed, paraffin embedded samples. The available specimens cover a range of oncology biomarkers, manufactured to standards including defined allelic frequencies.